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Abstract Over a period of 5 years, the Innovative
Medicines Initiative PROTECT (Pharmacoepidemiological
Research on Outcomes of Therapeutics by a European
ConsorTium) project has addressed key research questions
relevant to the science of safety signal detection. The
results of studies conducted into quantitative signal detec-
tion in spontaneous reporting, clinical trial and electronic
health records databases are summarised and 39 recom-
mendations have been formulated, many based on com-
parative analyses across a range of databases (e.g.
regulatory, pharmaceutical company). The
recommendations point to pragmatic steps that those
working in the pharmacovigilance community can take to
improve signal detection practices, whether in a national or
international agency or in a pharmaceutical company set-
ting. PROTECT has also pointed to areas of potentially
fruitful future research and some areas where further effort
is likely to yield less.
1 Introduction
The opportunities for effective signal detection in large
databases have improved substantially since the early days
of pharmacovigilance. In those early days, much effort
necessarily focussed on manual clinical review of incom-
ing reports—often in the form of handwritten or typed
reports of suspected adverse drug reactions (ADRs) by
pharmacovigilance experts. Adverse event reports, or sets
of reports, in some way triggering the suspicion of a clin-
ical reviewer would be further investigated by the reviewer
and in some instances go on to become signals with some
of these signals leading to further actions. While sophisti-
cated approaches to statistical signal detection had been
proposed and even tested in a limited methodological or
theoretical context [1–5], routine prospective screening
using tools and automated systems was a mere pipe dream.
Several decades later, systematic screening of adverse
event reports is not just a reality; it is today the de facto
standard in large datasets [6]. However, as adverse event
reports are exchanged electronically around the world, in
the tens of thousands on a daily basis, it is well accepted
that our capabilities for signal detection are far from per-
fect and should be improved. In addition, we are seeing a
significant shift of focus, beyond adverse event reports and
prescription event monitoring systems, on to the use of
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longitudinal observational databases and clinical trials for
signal detection. Although the former have been used
extensively in the past for epidemiological purposes, their
potential use for signal detection is novel and new
approaches for identifying safety signals in clinical study
data beyond basic comparisons of adverse event frequen-
cies have been slow to gain widespread use.
CIOMS VIII [7] was convened in part to address the
widespread and growing interest in quantitative analysis of
spontaneous reports and particularly the desire for guide-
lines around the appropriate use of such quantitative
approaches. There was also a need to contextualise the role
and use of such approaches, including disproportionality,
within a holistic signal management perspective. CIOMS
VIII was able to achieve these ambitions but also high-
lighted several areas of signal detection in spontaneous
report and observational data and in the use of terminolo-
gies that needed more research. PROTECT was set up to
address these, and a number of other important topics, in
signal detection.
The following recommendations1 relate to research
conducted into quantitative signal detection in spontaneous
reporting, clinical trial and electronic health records data-
bases conducted under the auspices of the Innovative
Medicines Initiative (IMI) PROTECT Work Package 3
(one of seven work packages) between September 2009
and February 2015. The PROTECT consortium (Pharma-
coepidemiological Research on Outcomes of Therapeutics
by a European ConsorTium; http://www.imi-protect.eu)
was a public–private partnership co-ordinated by the
European Medicines Agency (EMA) and received support
from the Innovative Medicines Initiative Joint Undertaking
(http://www.imi.europa.eu) under Grant Agreement No.
115004. Full details of IMI PROTECT, including specific
information about Work Package 3 and a detailed technical
report supporting the recommendations can be found at
http://www.imi-protect.eu/about.shtml.
In attempting to advance the science of safety quanti-
tative signal detection and with the overall goal of
increasing the efficiency of quantitative signal detection
practices, the scope of IMI PROTECT Work Package 3 has
been ambitious, with 12 separate work streams covering a
wide range of research questions and undertaken between
September 2009 and February 2015. To convert the
insights gained from these efforts into meaningful and
executable outputs, the following recommendations have
been developed: in total, 39 separate recommendations
have been formulated, many based on comparative
analyses across a range of databases (e.g. regulatory,
pharmaceutical company) and in several data sources
(spontaneous reporting, clinical trials and electronic patient
records). A further 25 recommendations for future research
are also offered. It is acknowledged that signal detection
relies on quantitative and qualitative elements and it should
be noted that the focus of Work Package 3 was primarily
concerning the former. The majority of recommendations
are based on the outcomes of the signal detection research
conducted under the auspices of IMI PROTECT Work
Package 3. However, in attempting to provide holistic and
unambiguous messages of how the work can impact good
signal detection practices, some reference to recommen-
dations beyond the strict scope of PROTECT is necessary.
2 Pre´cis of the Research and Recommendations
The studies undertaken though IMI PROTECT, which
provide the evidence base for each set of recommendations
that follow, are summarised here. For a full description of
the studies, refer to the cited original publication or tech-
nical report.
2.1 Timeliness of Quantitative Signal Detection
Using MedDRA Terms and Groupings
Different terms in standard medical terminologies can be
used to describe the same suspected ADR. Many organi-
sations rely on disproportionality analysis for first-pass
screening of large collections of individual case safety
reports, in which the observed rate of a drug and adverse
reaction reported together is compared with an expected
value based on their relative frequencies reported individ-
ually in the spontaneous reporting database. Confidence
intervals or statistical significance tests are used to provide
some protection against spurious associations and a certain
number of reports are generally required before an asso-
ciation can be detected. By grouping together related
medical terms for the purpose of analysis, the observed
count will increase, but so too may the corresponding
expected value. It is not known whether lumping or split-
ting is preferable for timely quantitative signal detection. A
previous study reported lower sensitivity but higher posi-
tive predictive value for MedDRA groupings than for
preferred terms (PTs) using cumulative data, but did not
evaluate the timeliness of statistical signalling [8].
The study of Hill et al. [9] sought to determine to what
extent the use of standard MedDRA2 groupings could
expedite the detection of disproportionate reporting pat-
terns for historical safety signals, relative to analysis by
1 The non-binding recommendations presented in this report repre-
sent the views of the authors and do not represent the views or
policies of the authors’ respective affiliations (unless by coincidence),
even if employees of those organisations at the time of preparing this
paper. 2 MedDRA is Medical Dictionary for Regulatory Activities.
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individual MedDRA PTs, separately, as is common
practice. Analyses were performed in the World Health
Organization (WHO) Global Individual Case Safety
Reports Database, VigiBase as of 5 February, 2010. The
scope of the study was restricted to 13 medical concepts
identified as having medium to high probability of being
drug related [10]. The ADRs consisted of 43 historical
labelling changes by the EMA related to one of the 13
medical concepts, derived from a previously published
reference set [11]. Each labelling change had an associated
index date indicating when the EMA first became aware of
the potential signal and initiated their investigation, which
was used for reference. For each medical concept, related
high-level terms (HLTs), narrow standardised MedDRA
queries (SMQs) and PTs were manually identified. The
latter were selected among the PT associated with either
the HLT or the SMQ for each concept. For each medical
concept, separate analysis of each PT was conducted and
also a joint analysis of all related PTs together as a custom
group. Disproportionality analysis was based on the
information component (IC), adjusted for country of origin
and year of submission to VigiBase (simultaneously),
through a Mantel–Haenszel-type stratification, as described
previously [12]. Lower 95 % two-sided credibility interval
limits of the IC (IC025) were computed retrospectively for
each quarter of a year from 1995 to 2010. For each level of
the hierarchy, the quarter in which IC025 first exceeded zero
was determined. For the analysis using individual PTs, this
was the first quarter that an IC025 value related to any
single PT in the group exceeded zero.
The study found no overall benefit in conducting signal
detection using MedDRA HLTs or SMQs compared with
using PTs. Some relatively minor gain in time to signalling
was seen when closely related (in a clinical sense) ADR
terms where grouped together and this should be explored
further in future studies.
2.2 Use of Novel Term Groupings Generated
by Knowledge Engineering Techniques
New methods based on knowledge engineering techniques
have been used to support the development of new
groupings of terms or new terminologies, respectively.
For example, the French Common Classification of
Clinical Procedures (CCAM) was built using artificial
intelligence tools from the European GALEN (General-
ized Architecture for Languages, Encyclopaedias and
Nomenclatures) project [13]. Version 11 of the Interna-
tional Classification of Diseases (ICD), which includes
reference to multiple factors such as body systems,
symptoms and causal agents, was developed using the
experience of international experts in medical informatics
[14]. Thus, knowledge engineering techniques can be
used to derive novel groupings of adverse event terms
based on semantic definitions of each term [15] and these
groupings may provide an alternative to the standard
groupings available in an adverse event terminology, such
as MedDRA HLTs or SMQs. In particular, knowledge
engineering may allow for a more flexible approach to
defining groups, based on the relevant dimensions for a
specific topic of interest.
Two PROTECT studies [16, 17] employed a bespoke
ontology (OntoADR [17, 18]) created using formal
definitions of MedDRA PTs. The formal definitions
were either inherited from mapped SNOMED clinical
terms or defined in semi-automatic or manual processes
[18]. The semantic definition for the MedDRA PT,
‘Upper gastrointestinal haemorrhage’, is illustrated as an
example:
Recommendation Rationale
For overall timeliness in
quantitative signal detection,
analysis can be performed at
the MedDRA PT level
The PROTECT study found no
advantage in conducting signal
detection at levels of
MedDRA above the PT level
and indeed observed a net loss
in timeliness of quantitative
signal detection from replacing
an analysis at the PT level with
one at a higher level of the
hierarchy [9]
Future research should evaluate
the false-positive burden for
signal detection at each level of
the terminology
The false-positive burden was out
of scope for the PROTECT
study [9]
Recommendation Rationale
Future research should evaluate
tighter custom-made groupings
of MedDRA PTs for signal
detection
Neither PTs nor HLTs are
universally ideal for
quantitative signal detection.
Gains in time by aggregating
PTs were observed in the
PROTECT study when the
terms were very similar, in a
clinical sense [9]
Future research should evaluate
simultaneous analysis at
different levels of the
terminology
Parallel analyses at different
terminological levels could
improve timeliness but have
resource implications [9]
Future research should explore a
broader range of ADRs
The PROTECT study was
restricted to a selection of 13
ADR categories [9]
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The concordance between groupings derived with
knowledge engineering techniques and standardised event
groupings, or manually derived groupings were studied and
found fair concordance between the terms included in the
standard and proposed groupings [16, 17, 19], as well as
high concordance between the corresponding measures of
disproportionality with randomly selected drugs in the
FAERS3 database [16, 17].
2.3 Development of a Structured Database of SPC
§4.8 as Reference Dataset
The information available from the Summary of Product
Characteristics (SPC) is increasingly used by computer
applications. For a computer program to make use of this
information, it must be coded according to a well-defined
and exhaustive dictionary. Probably the most commonly
used dictionary for ADRs is MedDRA. It is recommended
[20] that ADRs in the SPC be listed using exact (usually
preferred) terms from MedDRA but this does not always
occur in practice. Sometimes this is because the ADR
could be described using multiple MedDRA PTs and
would thus be difficult to communicate efficiently to clin-
ical staff in this format. Of course, no such problem arises
with a computer that can handle multiple terms efficiently.
Thus, it is worth investing the quite considerable effort
needed to convert the ADR information in the SPC for use
in computer applications. PROTECT took on the task of
creating a structured database of the ADR information in
section 4.8 of the SPC for all European centrally authorised
products using MedDRA as the coding dictionary.
Recommendation Rationale
Knowledge engineering
techniques may be considered
as an adjunct to the creation of
custom groupings and SMQs
designed for the selection and
extraction of case reports in
pharmacovigilance databases
The PROTECT studies show it is
possible to propose relevant
novel groupings when no
predefined grouping is
available in MedDRA for a
given safety topic (e.g.
anaphylactic shock or upper
gastric hemorrhages) [16, 17]
Additional research would be
necessary to validate if novel
groupings generated by
knowledge engineering
techniques can help in the
design of appropriate groupings
of MedDRA PTs for use in
signal detection or evaluation
Given the current state of
research, the clinical accuracy
of groupings generated by
knowledge engineering is such
that manual clinical review is
still required and this still needs




Consideration should be given
to piloting the use of
knowledge engineering in
developing groupings in other
ontologies for application to
other vocabularies and their
possible linkage
Given that it has been shown to be
possible to generate relevant
novel groupings in MedDRA, it
is reasonable to expect that it
would also be possible in other
ontologies, e.g. ICD10,
SNOMED
3 The Food and Drug Administration Adverse Event Reporting
System (FAERS) is a database that contains information on adverse
event and medication error reports submitted to the US Food and
Drug Administration.
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The coding of the SPC was a three-stage process. First,
strings of text corresponding to discrete concepts were
extracted manually and an exact match to the MedDRA
hierarchical dictionary at some level was sought using sim-
ple procedures in SAS. If this first matching failed, the EMA
sent the list of unmatched codes to the Uppsala Monitoring
Centre (UMC) where a fuzzy matching algorithm was run to
identify potential alternative matches to the strings [21]. The
final step was to subject remaining codes to expert evaluation
at the EMA and Bayer Pharmaceuticals.
An obvious application of machine-readable ADR
information arises in pharmacovigilance signal detection
systems. Such systems use ADR reports that are them-
selves coded in MedDRA and hence it is easy to use the
ADR dataset to determine immediately if a new signal of
disproportionate reporting (SDR) [22, 23] corresponds to a
known ADR. This eliminates the need for manual inspec-
tion of the SPC where the focus of the monitoring is the
detection of new risks. This use has already been tested
successfully at the EMA and the UMC and implemented
into their corresponding signal detection process. Another
potential application would be to alert doctors to a possible
known ADR using the information on medications and
clinical events contained in electronic health records. A
further use is in research on ADRs, for example, it could be
used to identify products with similar ADR profiles or to
help construct reference datasets for evaluation of quanti-
tative signal detection algorithms [21, 24]. If similar
databases are constructed in other regulatory systems, they
could also be used to investigate the consistency of regu-
latory decisions across these systems.
A difficulty with mapping textual SPCs to MedDRA is
that a given medical concept may map to several PTs.
When HLTs from MedDRA are used in the SPC this is
handled easily but non-MedDRA terms require consid-
erable thought. No systematic process exists to build up
groups of MedDRA PTs corresponding to broader med-
ical concepts. It is currently an incremental process that
improves over time as non-standard terms are discovered
and the mappings refined through repeated scrutiny, and
this area needs additional work. It would also be desirable
to extend the database to products authorised through
national procedures.
Recommendation Rationale
The structured database of ADRs
for centrally authorised
products may be used as a
reference to enhance
pharmacovigilance for these




The PROTECT database has
been used to provide a
reference in evaluating signal
detection methods and also to
identify known ADRs emerging
from routine signal detection
activity, hence reducing
unnecessary investigation.
Other potential uses have been
identified but not yet tested
Structured databases of ADRs
and their synonyms mapped to
MedDRA should be set up to
cover other products
The current database does not
address the majority of
products authorised under
mutual recognition or national
processes. Further work is
required if similar benefits are
to be realised in
pharmacovigilance systems
covering these products
A standard minimum structure
should be established for all
SPC ADR databases. The
PROTECT database provides a
useful template for this
structure
To maintain the utility of
databases and allow
combinations across databases,
a standardised core structure
will be essential although the
appropriate structure will
depend on the intended
functions of the database. Thus,
a coordinated approach with
wide consultation of intended
users would be needed. Co-
ordination of such an effort
could be undertaken by a large
regulatory agency or a cross-
industry organisation. For a




To facilitate signal detection,
exact MedDRA terms should
be used to identify ADRs in
SPC section 4.8 where feasible.
When an ADR involves very
large numbers of terms and
requires an ad hoc name,
mapping from this name to the
relevant MedDRA terms
should be maintained
This is essential to facilitate the
construction of machine-
readable data sources that have
a number of potential uses
including the facilitation of
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2.4 Comparison of Disproportionality Analysis
Methods Within and Across Spontaneous
Report Databases
Most pharmacovigilance departments maintain a system to
identify ADRs through analysis of spontaneous reports. The
majority of statistical methods used employ a dispropor-
tionality statistic calculated for each drug-event combination
in the dataset and a signal detection algorithm that consists of
a set of conditions that the disproportionality statistic and,
possibly, other statistics calculated for the drug-event com-
bination must satisfy for a SDR to be identified. The nature of
the spontaneous report databases in terms of size and drug
diversity varies between operators and it is unclear whether
any signal detection algorithm can be expected to provide
good performance in a wide range of environments. A
number of different disproportionality statistics are in use
[12, 29–31], but they are conceptually very similar [32–34].
The study of Candore et al. [35] compared the perfor-
mance of a number of commonly used signal detection
algorithms used across a range of spontaneous report
databases at national and international pharmacovigilance
organisations and individual pharmaceutical companies. A
set of 220 products was chosen and a reference set of
ADRs was compiled based on SPC and company core data
sheets. Among four companies, one national agency and
two international spontaneous report databases, 15 quan-
titative signal detection algorithms based on five dispro-
portionality statistics were tested using a subset of products
that fell within the pharmacovigilance responsibilities of
the respective database owners. Signals of disproportionate
reporting were identified at monthly intervals and classified
as true positives if they corresponded to an entry in the
reference set. To measure the (algorithm’s) performance,
these results were summarised as sensitivity and precision
(specifically, the positive predictive value) for each algo-
rithm in each database. Time to signalling was also
investigated, as early detection is an important contributory
factor to effective pharmacovigilance.
Different algorithms gave very different levels of signal
detection performance across all spontaneous report data-
bases tested. However, increases in sensitivity were gen-
erally associated with a decrease in precision and no
method clearly dominated all others. The performance is
strongly dependent on the thresholds and other rules based
on the disproportionality statistics that define a statistical
signal. However, the different disproportionality statistics
did not themselves influence the achievable performance:
the choice of signal detection algorithm was much more
important than the choice of disproportionality statistic.
Absolute performance of the same algorithm might be very
different between one spontaneous report database and
another but the relative performance of two algorithms was
generally similar in different databases. Over the lifetime
of a product, there is a reduction in precision of any
quantitative signal detection algorithm.
The changes in sensitivity and precision obtainable by
replacing one quantitative signal detection algorithm with
another are predictable. However, the absolute performance
of a method is specific to the spontaneous report database and
is best assessed directly on that database. The limits of per-
formance of the current disproportionality statistics are
similar and new methods, involving substantially different
approaches, may be required to gain appreciable improve-
ments using spontaneous reporting data.
Recommendation Rationale
Computerised text processing to
help in mapping non-standard
descriptions of ADRs to
MedDRA codes should be
considered both for efficiency
and consistency of coding
practice
The approximate matching
system was used to find
appropriate MedDRA terms
when non-standard terminology
was used in the SPC. This was
usually successful and also
much more efficient than
human intervention alone [28]
In setting up a database of ADRs,
a programme of maintenance
should be established to reflect
changes to the SPC from
emerging safety issues or
MedDRA version changes
Around half the ADRs listed in
SPCs are added as a result of
post-authorisation activities and
hence the database will require
continuous attention to keep it
up to date
Consideration should be given to
establishing the value and
feasibility of having direct links
between databases of SPC data
and other product information
sources to prevent the need for
duplicate data sources, or avoid
repetition in the types of data
collected in the different
sources
Lists of product ADRs are
currently maintained by
regulators and by MAHs. These
may conflict either in detail or
in coding conventions. Even





Choice of a disproportionality
statistic for signal detection





statistics are currently used in
data mining spontaneous report
databases. All these can achieve
similar overall performance by
choice of appropriate signal
detection algorithm. Thus,
choice should be based on
criteria other than signal
detection performance. Factors
that might be considered
include the computing
requirements to run the system,
the ease of maintaining and
adapting the system and
whether the operation of the
system can be easily
communicated to non-
statisticians [35]
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2.5 Use of Subgrouping and Stratification
in Disproportionality Analysis
Spontaneous report databases cover a range of products
aimed at diverse medical conditions and used across a
broad range of patient populations. This diversity is
important as, for example, vaccines are given to healthy
subjects, often children who are likely to have fewer
underlying medical conditions and consequently different
reported background adverse events than the main popu-
lation of patients that use other medicines. Many quanti-
tative signal detection algorithms disregard this diversity
and give equal weight to information from all products and
all patients when computing the expected number of
reports for a particular drug-event pair, which may result in
signals either being masked or false associations being
flagged as potential signals. Stratification and subgroup
analyses are generally used in epidemiology to reduce
confounding and highlight effect modification. Both of
these approaches may also have advantages in quantitative
signal detection.
Recommendation Rationale
Consideration should be given to
the choice of signal detection
algorithm used with
disproportionality statistics




In contrast to the choice of
disproportionality statistic, the
choice of signal detection
algorithm to define a SDR can
provide very different levels of
quantitative signal detection
performance in terms of
sensitivity, precision and time
to signal. Hence, these criteria
must be carefully selected on
the basis of empirical evidence
[35]
For moderate to large
spontaneous report databases,
the relative performance of a
quantitative signal detection
algorithm in one database can
be predicted from research in
other databases
In the PROTECT study, signal
detection algorithms with good
signaling properties (in terms of
sensitivity and positive
predictive value) compared to
other signal detection
algorithms in one spontaneous
report database also had
relatively good signaling
properties in other spontaneous
report databases. The databases
were both regulatory and
company based and ranged in
size from about 500,000 to
5,000,000 reports. Hence,
relative performance in
moderately large databases can
be reliably inferred from
evaluations in other settings
[35]
Absolute performance of the
selected quantitative signal
detection algorithm must be
validated in the target
spontaneous report database
Although the relative
performance of signal detection




may vary substantially. Hence,
it is advisable to test the chosen
disproportionality statistic with
a range of signal detection
algorithms within the target
database [35]
Consideration should be given to
the effect of reduced positive
predictive value with time on
the market
There appears to be a reduction
in precision with time and
hence it may be more
productive to put additional
effort into the evaluation of
signals from newer products.
This finding has been validated
excluding ADRs identified
prior to authorisation from the
reference database but further
work is ongoing to characterise
this effect [35]
Recommendation Rationale
Consideration should be given to
carrying out comparisons of
quantitative signal detection
methods across spontaneous
report databases matching at the
drug-event combination level
rather than averaging over all
drug-event combinations
It is possible that some ADRs
may be more easily found in
some databases. This was not
investigated in PROTECT
It would be useful to conduct
research to establish
empirically the best method for
quantitative signal detection in
combination products
Combination products and single
substances are often treated as
unrelated in signal detection
systems; a question remains
whether combining data from
these products will provide
more or less accurate detection
of signals
Consideration should be given to
establishing a framework for
selecting the best quantitative
signal detection algorithm to
suit the organisational goals and
resource available within a
pharmacovigilance group
Our research has shown a
predictable trade-off between
sensitivity and precision as far
as purely quantitative signal
detection algorithms are
concerned. However, the means
of striking the correct balance
between sensitivity and the
concomitant burden of false
positives for a given
organisation requires careful
consideration
Recommendations for Signal Detection from IMI PROTECT 475
Other published studies have suggested some benefits of
stratified and subgroup analyses but often the analyses
included only a few key covariates or study products, and
were conducted in single databases [36–44]. It is not clear
how generalisable these results are to other spontaneous
report datasets of different sizes and characteristics.
Additionally, to our knowledge a head-to-head comparison
of stratified and subgroup analyses against a reference
standard has not been conducted.
The study of Seabroke et al. [45] investigated the impact
of stratification and subgrouping in signal detection algo-
rithms in spontaneous report databases of different sizes and
characteristics using a range of key covariates (age, gender,
calendar time period, country of origin, vaccines/non-vac-
cines, event seriousness, reporter type and report source).
Signal detection performance was measured against a ref-
erence standard. Disproportionality analyses were con-
ducted using either stratified or subgroup approaches and
compared with an unstratified crude analysis. Stratified and
subgroup analyses calculated disproportionality statistics
within each individual stratum separately. For the stratified
analyses, these were combined into a single value using a
Mantel–Haenszel approach, whereas for subgroup analyses,
a positive signal was counted if any of the individual strata
met the signal criteria. The results were presented as sensi-
tivity and precision (positive predictive value) for each
approach calculated using a reference set of ADRs compiled
from the SPC and company core data sheets as a proxy for
true positives. Additional analyses included investigating the
benefit of combined subgroup/stratified variables and also
investigating the impact of a permutation analysis that used
randomly split strata of equal size to a real variable of interest
and compared the results with those for the real variable.
Whilst the spontaneous report databases employed in
this study included large international, national and
industry datasets, the results may not be generalisable to all
spontaneous report databases, particularly those with a
small volume of reports. The results from this study
showed that subgroup analyses consistently performed
better than stratified analyses in all databases. Subgroup
analyses were also shown to provide clear benefits over
crude analyses for some databases whilst stratified analyses
were not found to increase either sensitivity or precision
beyond that associated with analytical artefacts of the
stratified analysis.
Recommendation Rationale
Subgroup analyses may be
beneficial in routine first-pass
signal detection and should be
considered. Stratified/adjusted
analyses are unlikely to provide
added value
In spontaneous report databases
with over 0.5 million reports
with broad diversity of
products, subgroup analyses




analyses were not found to
increase either sensitivity or
precision beyond random
variation [45]
Subgroup analyses can be
considered beneficial in large
international spontaneous
report databases with over 2
million reports. Smaller
datasets especially those with
reports from only one country
may need to consider a likely
tradeoff between increased
precision with some loss of
sensitivity if subgroup analysis
was to replace a crude or
adjusted analysis
Subgroup analyses within the
larger international datasets
consistently showed benefits in
both precision and sensitivity




For the smaller spontaneous
report databases, a gain in
precision tended to result in
some loss of sensitivity
particularly for the stricter
disproportionality method/
threshold and for the regulatory
dataset with reports from only
one country [45]
Subgrouping by seriousness of
ADR or routinely excluding
legal cases is unlikely to
provide benefits in signal
detection in terms of increased
sensitivity or precision
Subgrouping by seriousness of
the ADR defined using the IME
lista had little effect on
sensitivity or precision in any
spontaneous report database.
An analysis excluding cases
submitted by lawyers also had
little effect in all spontaneous
report databases apart from the
largest international database,
which showed an increase in
sensitivity and precision when
legal cases are excluded [45]
Subgrouping by gender, reporter
type and 5-yearly time points
may provide modest
improvement in precision in all,
and sensitivity in some,
spontaneous report databases
Subgrouping by gender, reporter
type and 5-yearly time points
showed a modest improvement
in precision for all spontaneous
report databases and improved
sensitivity for larger and
international databases.
Implementation of these
subgroup analyses into routine
signal detection may provide
some benefit [45]
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2.6 Influence of Masking on Disproportionality
Analysis
Disproportionality analysis uses the spontaneous report
database itself as the basis for computing an expected
number of reports on a particular drug and adverse event.
This is based on the assumption that true causal relation-
ships between drugs and events do not influence the overall
reporting rates and that the degree of under- (or over-)
reporting for a given event is approximately the same for
all drugs. In practice, this assumption may be invalid for
some drugs and events in a spontaneous reporting database.
For example, attention to a real or perceived safety issue in
the medical community or in public media may increase
the reporting rate for that drug-event pair to such an extent
that the overall reporting of that event is affected and
potentially masks alerts from other drugs [46–51].
The two studies that made up this PROTECT work
package [49, 50] looked at the impact of masking on dis-
proportionality analysis. An algorithm was used to generate
a masking ratio whereby the masking effect of one drug on
another can be estimated for a specific event and suggests a
simplified version valid under certain conditions. A simu-
lation study was performed that focussed specifically on
comparing differences between the simplified and exact
masking ratio [49]. The impact of different approaches to
treating the reports was also explored, including both the
suspected masking drug and the suspected masked drug as
concomitant medicines. In a follow-on study, the extent
and impact of masking was studied in two spontaneous
Recommendation Rationale
Subgrouping by age, country or
continent of origin, or a
combination of these variables,
may confer improved precision
in all and enhanced sensitivity
in some spontaneous report
databases
Subgrouping by age, country of
origin, continent of origin and a
combination of these variables
showed the highest
improvement of precision in all
spontaneous report databases
and sensitivity in the larger
databases. Implementation of





vaccines should not be
implemented without careful
consideration of the desired
effect
Subgrouping by vaccines/non-
vaccines resulted in a decrease
in both precision and sensitivity
in all spontaneous report
databases. This was almost
exclusively driven by the
vaccines subgroup. These
effects were owing to the
suppression of listed vaccine
ADRs as a result of comparing
vaccines to each other. This
may be desirable for certain
reactions e.g. injection-site
reactions but undesirable for
other more serious reactions
e.g. Guillian–Barre syndrome
[45]
Where subgrouping by variables
with considerable missing data
(e.g. age, gender) is undertaken,
consideration should be given
to including a stratum for
unknown rather than excluding
these cases
Including missing data in the
subgroup analyses for age and
gender increased sensitivity in
all spontaneous report
databases but tended to also
decrease precision. In
spontaneous report databases
with higher levels of missing
data (20? %) the increase in
sensitivity was greater than the
decrease in precision [45]
Subgrouping with a threshold
based on number of reports
may benefit from basing the
threshold on the entire drug-
event combination rather than
within each individual stratum
Results for subgroup analyses
that used an overall threshold of
n applied to the whole drug
event combination showed
large increases in sensitivity but
with loss of precision. Further
validation would be needed
within each organisation to
ascertain whether this approach
is sustainable in respect of
resources available to evaluate
an increased number of false
positives [45]
Recommendation Rationale
Future research should evaluate
the use of subgroup analysis in
parallel with crude and/or
adjusted analysis
Results for subgroup analyses that
used an overall threshold of
n applied to the whole drug event
combination showed large
increases in sensitivity but with
loss of precision. Further
validation would be needed
within each organisation to
ascertain whether this approach
is sustainable in respect of
resources available to evaluate
an increased number of false
positives [39]
a The EMA Important Medical Event Terms (IME) list (https://
eudravigilance.ema.europa.eu/human/textforIME.asp)
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reporting data sets: EudraVigilance and Pfizer’s sponta-
neous report database [50]. The latter evaluated the impact
of removing from the analysis for each ADR the drug with
the highest masking ratio. It was found that the drugs
inducing the highest masking effects tended to be those that
are known to cause the ADR in question. Under the con-
ditions of the study (assuming that each ADR is masked by
exactly one drug), it was rare that the unmasking analysis
affected whether a drug-event pair was considered to be
disproportionally reported or not. However, it is important
to note that the drug-event pairs affected in this way pri-
marily involved rarely reported ADRs.
2.7 Drug–Drug Interaction Detection
Adverse drug–drug interactions (DDIs) harm large num-
bers of patients every year. Not all DDIs are known when
new medicines are made available to the general public,
but individual case reports may enable post-marketing
detection. Earlier studies have indicated that statistical
measures for DDIs that use additive baseline models per-
form better than those that use multiplicative baseline
models [52, 53] but no broad evaluation has been reported
in the literature. A study was conducted to compare the
sensitivity and specificity of different statistical measures
for ADR detection against established and emerging
adverse DDIs, respectively.
Analyses were performed in VigiBase where four sta-
tistical measures for DDI detection were evaluated: one
based on regression with a multiplicative baseline model
[53], one based on regression with an additive baseline
model [53], one shrinkage disproportionality statistic with
a multiplicative baseline model [52] and one shrinkage
disproportionality statistic with an additive baseline model
[52]. The reference set for known interactions consisted of
74 established DDIs and 29 pairs of drugs with an ADR for
which there was no empirical support for a DDI. The ref-
erence set for emerging DDIs included 324 adverse drug
interactions added to Stockley’s Interaction Alerts between
2007 and 2009, and 324 9 20 combinations with two
drugs that were not listed together as known to interact in
the same reference, in 2009. The majority of the ADRs
were investigated at the Meddra PT level.
The study was limited to statistical interaction measures,
whereas recent research has suggested that predictive
models accounting for multiple aspects of strength of evi-
dence may perform even better [54]. The algebra of the
Recommendation Rationale
Quantification of the masking
effect of drugs on adverse
reactions or adverse reactions
on drugs could be used as a
diagnostic tool of the extent of
masking at two levels:
For determining, based on the
general characteristics of a
spontaneous report database, if
the application of an unmasking
algorithm would be worthwhile
At the product-event pair level,
if a specific concern is raised
about a potential masking effect
driven by another product or
another group of products
Results indicate that many drugs
and adverse reactions are not
affected by masking. Avoid
complicating the analysis of data
by adding an unmasking
procedure when masking is not
an issue. Formulas for assessing
the effect of masking can be
found in papers by Maignen et al.
[49, 50]. As the characteristics of
the spontaneous report database
change over time, it is still
interesting to monitor the extent
of masking periodically. During
signal evaluation, some
evaluation of the masking effect
could be performed at the level of
the product-event pair [49, 50]
If the masking effect of drugs on
adverse reactions or adverse
reactions on drugs is
substantial, applying an
unmasking algorithm should be
considered
Reducing the effect of masking
can increase the sensitivity of
quantitative signal detection
and, in principle, result in
earlier identification of new
drug-event associations [49, 50]
If false negatives are a major
concern, unmasking of drugs
and/or adverse reactions can be
used in parallel with standard
disproportionality analysis to
improve sensitivity and
timeliness but this benefit must
be balanced against the cost in
increased evaluation of false
positives
If unmasking and standard
disproportionality analyses are
used in parallel, sensitivity will
be equal to or higher than that
of standard disproportionality
analysis alone, but parallel
analyses of the data also
increase the false-positive rate,
from spurious associations
[49, 50]
Future research should explore
the effectiveness of unmasking
in terms of true/false positives
revealed by an algorithm
In the absence of public health
evidence from prospective
studies on the benefits of
removing the masking (or
situations in which unmasking
could be beneficial), the use of
a particular algorithm should be
directed by the rate of true
signals/false positives revealed
by the removal of the
unmasking effect [49, 50]
continued
Recommendation Rationale
Future research should compare
disproportionality-based
approaches for unmasking to
other statistical approaches
(e.g. logistic regression models)
that could also be used to
account for masking effects
This was outside of the scope of
the PROTECT studies and
there appears to be no
published research on this topic
The use of simple unmasking




explored in a future study
Results indicate that the
performance of the simplified
methods is comparable to that
of more complex methods
while the computational
complexity is reduced and
transparency improved, but
further research is needed to
fully explore this on datasets
with different properties
[49, 50]
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statistical interaction measures is such that additive models
impart superior sensitivity regarding the detection of DDIs
compared with multiplicative measures, at any given value
for the threshold. However, the additive models used in this
study also demonstrated better specificity compared with
the multiplicative models. Thus, statistical interaction
measures with additive baseline models outperformed
those with multiplicative baseline models for both estab-
lished and emerging adverse DDIs. However, given the
small number of cases attributed to the interacting drugs
together, both models gave low sensitivity (\20 %) for
emerging adverse DDIs, at conventional signalling criteria.
Recommendation Rationale
Statistical interaction measures
with additive baseline models
should be preferred over those
with multiplicative baseline
models for detecting signals of
DDIs in spontaneous report
databases
Statistical interaction measures
with additive baseline models
provided better sensitivity and
equal or better specificity for
both established and emerging
DDIs [55]
Future research should explore
how statistical interaction
measures with additive baseline
models can best be
incorporated in broader
predictive models of adverse
drug interactions, and in routine
signal detection
This was out of scope for the
PROTECT study, but recent
research has found that
predictive models accounting
for multiple aspects of strength




Individual case reports of suspected harm from medicines
are fundamental for signal detection in post-marketing
surveillance. Their effective analysis requires reliable data
and one challenge is report duplication. These occur when
multiple unlinked records are recorded describing the same
suspected ADR in a particular patient. Report duplication is
known to occur for a diverse range of reasons, including
reporting of an ADR from multiple primary sources,
requirements for marketing authorisation holder reporting
of literature cases (and subsequent retransmission), and
technical or administrative issues [56]. De-duplication of
data is also widely understood to be a time-consuming
process; however, little research had been undertaken prior
to PROTECT on the efficiency of different de-duplication
methodologies. Duplicate ICSRs are known to distort sta-
tistical screening [56] both increasing the numbers of false-
positive and false-negative signals. The net effect of
duplicates (and de-duplication techniques) is unknown, and
may not be consistent across all products in the database;
however, where there is a significant impact there is
potential for the cases to mislead clinical assessment.
Many organisations rely on rule-based duplicate detec-
tion methods, which rely on exact matching of a number of
elements within individual case safety reports and dis-
playing the putative duplicate cases for review. Rule-based
approaches can vary significantly in their complexity and
based on the fields used, and may consider patient, reporter,
drug or reaction details, or a combination of them. The
study compared methods [57] used in the UK, Denmark
and Spain. The UMC had previously published a proba-
bilistic record matching algorithm that indicates the like-
lihood of cases being duplicates (vigiMatch [58]) as an
alternative to rule-based approaches. The PROTECT study
attempted to quantify the benefits (or disbenefits) of the
different approaches used by PROTECT consortium
members.
A first phase of the study aimed to evaluate probabilistic
record matching for duplicate detection compared with
rule-based approaches. Studies considered positive pre-
dictive value and numbers of false positives of different
approaches, and in addition attempted to characterise the
main causes of duplication. Initial research was undertaken
using the WHO Global Individual Case Safety Reports
Database, VigiBase, for reports submitted between 2000
and 2010. Suspected duplicates for the UK, Denmark, and
Spain were reviewed and classified by the respective
national centre. This included evaluation to determine
whether confirmed duplicates had already been identified
by in-house rule-based screening. A second phase of the
study directly compared results from the MHRA’s rule
based approach to the UMC’s probabilistic record match-
ing approach using data received in the MHRA’s Sentinel
database during 2013.
Probabilistic record matching performed positively
when compared with rule-based approaches. Specifically,
probabilistic record matching demonstrated a high predic-
tive value above that of rule-based methods and is expected
to improve efficiency and accuracy of duplicate manage-
ment. The study showed very few false positives suggest-
ing it may be possible to increase sensitivity while ensuring
false-positive rates are kept at a reasonable level. The study
[57] highlighted that case management system changes or
upgrades can occasionally result in large numbers of
duplicates, either in the source system, or those external to
the organisation. It was also noted that proliferation of
duplicated cases within databases occurred as a result of
rapid submission and re-transmission of cases to multiple
stakeholders made possible by electronic systems. This
emphasises the need for swift and robust duplicate detec-
tion procedures at each organisation. Data privacy
requirements were noted as a barrier to the most effective
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duplicate detection and it was considered that approaches
to deidentifying data (for example, scrambling dates and
patient initials) in a way that permits duplicate detection
should be pursued to allow for effective duplicate detection
in databases that pool reports from different sources.
Although beyond the scope of the PROTECT study,
further evaluation should be undertaken to understand the
feasibility and impact of automatic exclusion of potential
duplicates from quantitative signal detection algorithms.
Such an approach may help ensure independence of
reports, which is a fundamental assumption underlying the
computation of confidence intervals for all disproportion-
ality statistics; however, it equally may remove clusters of
reports from the same reporter that may be important for
patient safety. A better understanding of the reasons for
related cases that are not considered duplicates, and their
scientific implications for signal detection will help deter-
mine if this is a viable approach.
2.9 Relationship Between Disproportionality
Measures (i.e. PRR) and Risk Estimates
Spontaneous reports are only submitted when a patient
exposed to a medicine experiences a suspected ADR and
the reporter decides to report the case. It is difficult to
determine the extent to which the numbers of these
reports may help to reflect a measure of association of
adverse outcomes in the drug-exposed population. Thus,
the quantitative data in spontaneous reporting systems,
while being useful in detecting new signals of drug-
event associations, are not easily interpretable in terms
of clinical impact. Nevertheless, quantitative signal
detection systems consider threshold levels for dispro-
portionality measures and therefore higher values of
disproportionality statistics are one of the factors that
influence the decision to investigate particular drug-
event combinations. Hence, it makes sense to ask whe-
ther there is a direct relationship between the magnitude
of disproportionality statistics and the magnitude of the
association between a product and an adverse effect
from pharmacoepidemiological studies.
A study was conducted to determine the proportional
reporting ratios (PRRs) for a set of known ADRs and
compare them with estimates of association from formal
epidemiological studies [59]. A set of 15 confirmed
ADRs were selected from the initially identified dataset
of pharmacovigilance driven European Union regulatory
actions and for which relative risk estimates from formal
studies were available and were considered to provide
Recommendation Rationale
Probabilistic record matching
should be considered as an
alternative to rule-based
methods for duplicate detection
in pharmacovigilance
Probabilistic record matching
demonstrated a high predictive
value above that of rule-based
methods in our study, and is
expected to improve efficiency
and accuracy of duplicate
management [57]
Care should be taken to avoid
case duplication during system
changes/upgrades, considering
both internal aspects and case
transmission to external
organisations
Our study showed that such
changes on occasion resulted in
very large numbers of
duplicates [57]
Rapid electronic re-transmission
of spontaneous adverse drug
reaction reports between
databases can increase the
number of duplicates to the
extent that disproportionality
statistics are are significantly
affected, emphasising the need
for swift and robust duplicate
detection and management
processes in databases that
employ electronic data
exchange
There are a large number of
duplicates in spontaneous
reporting databases, which are
shown to affect quantitative
signal detection scores. Rapid
transmission of cases by
electronic systems exacerbates
this issue, meaning that
accurate (and ideally, non-
burdensome) duplicate
detection processes are required
to mitigate this unwanted
impact on disproportionality
statistics [57]
Further work should be
undertaken to explore lowering
the threshold for the tested
probabilistic record matching
method and methods in general
to evaluate the balance of false
positives and negatives
Our study showed very few false
positives, so it should be
possible to increase sensitivity
while ensuring false positive
rates are kept at a reasonable
level [57]
Recommendation Rationale
Further evaluation should be
done to understand the impact




This was beyond the scope of the
PROTECT study. If this
approach proved successful
manual duplicate detection
activities could be eliminated
resulting in time/resource
savings [57]
Approaches to deidentifiying data
(for example, scrambling dates
and patient initials) in a way
that permits duplicate detection
should be pursued to allow for
effective duplicate detection in
databases that pool reports from
different sources
This will reduce the negative
impact of data privacy laws, for
duplicate detection in
international databases [57]
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well-established evidence supporting the respective reg-
ulatory actions. Prior to any calculation of PRR, the
studies were collated and a best estimate of the risk ratio
selected on the basis of pre-specified rules. When
available, this estimate was that determined during the
European Union regulatory assessment. At the same
time, an estimate was made of the date at which each
ADR was first publicly recognised.
Only after the risk ratio was decided upon was the
PRR calculated by reconstruction of the spontaneous
reporting data system at the predetermined date of first
recognition in the medical community of the ADR. The
primary analysis used the EudraVigilance spontaneous
report database and an additional analysis was carried
out in FEDRA, the Spanish national spontaneous report
database. Case definitions for the ADR of interest were
developed for PRR calculations for each drug-event pair,
aiming to reproduce the case definition as used in the
epidemiological studies providing relative risks. An ini-
tial dataset of 78 drug-event pairs was obtained follow-
ing the initial inclusion criteria. Following the exclusion
criteria, 15 drug-event pairs were finally selected. The
pairs include 13 different ADRs and 14 different drug-
s/classes. Four of the ADRs represented class effects.
Four topics were related to outcomes of safety referrals
concluding in a CHMP Opinion and 11 were recom-
mendations from the Pharmacovigilance Working Party
to CHMP or to National Competent Authorities. Eleven
of 15 drugs were non-centrally authorised medicines and
four were centrally authorised in the EU.
An orthogonal regression model showed a significant
association between relative risks and PRRs. This sug-
gests that, in some cases, there is a relationship between
the PRR calculated immediately prior to first awareness
of the safety topic and estimates of relative risk taken
from published epidemiological studies, where the signal
turned out to be confirmed. It is noted that no validation
of the model has been performed and that despite the
good correlation shown between RRs and PRRs in this
exercise, it is emphasised that PRR cannot replace RR.
Thus, calculation of PRRs from spontaneous reporting
databases should not replace nor delay the performance
of formal epidemiological studies but could however be
an indicator of the likely clinical importance of the
adverse reaction, should the signal be confirmed subse-
quently [60].
Recommendation Rationale
It may be possible to use the PRR
at the early phase of the
analysis of a new safety signal
as an indicator of the likely
strength of the association,
should the signal be confirmed
The PRR observed before general
awareness of an ADR shows a
good correlation with the
strength of the association in
terms of relative risk or odds
ratios later established by
controlled studies. However,
the PRR is not a direct
estimator of the risk ratio and
should be considered only in
the absence of any more
reliable evidence. The caveat
‘should the signal turn out to be
confirmed’ must be observed.
The study analysis does not
compare the distribution of
PRR values for ‘true’ and
‘false’ signals of
disproportionate reporting and
no inference can be made about
whether the initial magnitude of
PRR gives information about
the nature of the association
(causal or otherwise) [59]
Following the initial detection of
a signal of a specific drug-event
association, PRR values based
on clinical definitions of the
adverse event may serve to
provide an estimate of the
likely size of clinical effect and
be included among the criteria
for initial prioritisation of its
assessment
This study shows that, at least in
this selected set of study cases,
the underlying relative risk
seemed to influence both the
direction and magnitude of the
PRR calculated with a similar
case definition of the adverse




diverse data sources and signal
detection systems, the results





Consideration should be given to
repeating these analyses in
other ADR datasets to see
whether they can be replicated
and, if they can be, to establish
the relevant scale factor
PRR values generated in different
ADR datasets are unlikely to be
the same. Other IMI PROTECT




algorithms in different ADR
datasets. However, to date no
attention has been paid to
describe and explain
differences in the calculated
PRR values in different datasets
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2.10 Signal Detection in Longitudinal Observational
Data
Post-marketing surveillance aims to identify and charac-
terise risks of medicines. At present, signal detection is
predominantly based on individual case reports, but the use
of electronic health records and insurance claims to detect
ADRs is an area of active research [61–64]. While some
work has focussed on traditional sequential approaches and
looking to use them for signal detection, new methods have
also been adapted or proposed [65–68]. Other publications
have highlighted the challenges and limitations of using
longitudinal observational data for signal detection [69, 70].
The objectives of the three studies that made up this
PROTECT work package were (1) to better characterise the
opportunities and challenges for prospective signal detection
in longitudinal electronic health data, including the devel-
opment and evaluation of a process for the structured
assessment of potential safety signals from electronic health
records; (2) a comparison between exploratory and confir-
matory analyses of longitudinal electronic health data and;
(3) a performance evaluation of quantitative signal detection
in longitudinal electronic health data and individual case
reports, respectively, for emerging safety signals. All anal-
yses were performed in The Health Improvement Network
(THIN4) database of longitudinal electronic health records
from general practices in the UK.
The comparison between exploratory and confirmatory
analysis was based on 13 published studies of possible ADRs
in THIN [71]. The selected studies listed a total of 56 drug-
event pairs that were included in the analysis. For each pair,
the analysis results of the study (positive or negative) were
compared with those that would result from analysis with
standard design choices for a calibrated self-controlled
cohort analysis in THIN. Observed differences were closely
scrutinised to identify areas of possible improvement for the
standard implementation of the design, for exploratory
analysis. In our comparison to published epidemiological
studies, a common discrepancy was that the epidemiological
study performed analysis for all drugs in a class together and/
or for a number of related medical events together, which
improves power. However, our detailed review often found
substantial and important differences among different drugs
in the same class or among different medical events in the
same category. Clearly, more research is needed to minimise
terminological obstacles for exploratory analysis of longi-
tudinal data, as well as across the different data streams [70].
None of the false positives were considered to represent a
chance association: all were considered to be the result of
systematic variability.
For prospective identification of potential signals in
electronic health records [72], a questionnaire for struc-
tured assessment was designed and iteratively refined
through pilot testing. It covered aspects such as the nature
of the temporal pattern, the presence of co-medications
associated with the medical event, the likelihood of con-
founding by underlying disease, and other alternative
explanations for observed temporal associations. In real-
world use, its purpose would be to provide analysis and
decision support for potential signals identified through
prospective and open-ended screening of longitudinal
electronic health data. For the purpose of the study, drug-
event pairs temporally associated according to a calibrated
self-controlled cohort analysis in THIN were randomly
selected for review. Six assessors trained in pharmacovig-
ilance and/or epidemiology participated in the main study
and each evaluated up to 20 temporally associated medical
events per drug, for seven randomly selected drugs [72].
Our analysis highlighted a number of potential safety sig-
nals in electronic health records that merit further review.
These range from life threatening to those that are less
serious, but important for patients and for adherence.
However, three out of four temporal associations identified
in the initial screen could be dismissed from further eval-
uation after the initial review. In other words: without a
review, the majority of the highlighted associations would
have been false positives. A minority of the dismissed
associations were considered to be owing to random vari-
ability; most were the result of biases and other systematic
effects [72].
Recommendation Rationale
Consideration should be given to
further exploring whether PRRs
adjusted by subgroup variables
improves the correlation with
measures of association from
studies
The findings from an IMI
PROTECT study on sub-
grouping and stratification [45]
suggest that subgrouping may
be a useful strategy to try to
improve the correlation
between the PRR and the
estimates of risk from studies
Consideration should be given to
exploring whether PRRs
calculated for single
MedDRA PTs as is in
EudraVigilance monitoring
behave in the same way as the
clinically defined case
definitions in terms of
correlation with measures of
association from studies
The medical concepts used in the
studies to derive the estimates
of relative risk often described
broader medical concepts than
the MedDRA PT level used in
EudraVigilance for the PRR
screening analysis (see also





4 THIN is an electronic medical record data resource including over
12 million individual patients from the UK, with over 3.8 million
currently active patients. The electronic medical records are collected
from general practices in primary care (http://www.ncbi.nlm.nih.gov/
pubmed/22828580).
.
482 A. F. Z. Wisniewski et al.
The performance evaluation of quantitative signal
detection in longitudinal electronic health data and sponta-
neous reports was based on a reference set of 264 historical
safety signals derived from a previously published study
[11], and 5280 negative controls. The literature is very sparse
on such comparisons. One example is from Trifiro` et al. [73],
who as part of the EU-ADR (European Commission spon-
sored project ‘Exploring and Understanding Adverse Drug
Reactions by integrative mining of clinical records and
biomedical knowledge’), looked at the number of drug-event
combinations that were highlighted as disproportional in
each of the data sources. Analyses were performed in THIN
and VigiBase, each backdated to the end of 2004, to match
approximately the time of the historical signals. The analysis
in VigiBase was repeated with a restriction to reports origi-
nating only from the UK. The retrospective evaluation
against historical safety signals for European centrally
authorised products showed that none of them could be
detected in THIN with the method we used, prior to the initial
signal at the EMA. In many cases, this was because of the
drug not being available on the UK market at the time, or the
drug or medical event not being reliably captured in primary
care. In contrast, some of the positive controls could be
detected in VigiBase, even when we restricted the analysis to
individual case reports originating from the UK.
Recommendation Rationale
Longitudinal observational data
should be further explored as a
complement to signal detection
using individual case reports
but cannot currently replace
individual case reports for this
purpose
Individual case reports of
suspected harm from medicines
have a proven value for safety
signal detection. However, they
are not optimal for detecting
increased rates of multifactorial
adverse drug reactions with high
background incidence.
Longitudinal observational data
provide the basis for
epidemiological evaluation of
such associations and should in
principle enable their initial
identification. However, we lack
evidence to suggest that signal
detection in longitudinal
observational data can match
the performance of signal
detection in individual case
reports for all drugs and medical
events. In our evaluation of
historical safety signals from the
EMA, none of the positive
controls could be detected in the
THIN database at an early stage,
whereas this was possible in
VigiBase for some of the
signals, even when we
considered only the subset of
the UK individual case reports
[72]
Recommendation Rationale






Clinical review of statistical
signals is fundamental in
evaluating signals arising from
spontaneous report databases.
In our study of structured
assessment for prospective
identification on safety signals
in electronic health records,
three out of four temporal
associations identified in the
initial screen could be
dismissed from further
evaluation after initial review.
Without review, the majority of
the highlighted associations
would have been false positives
[72]
To the extent possible, temporal
associations detected in
longitudinal observational data
should be further explored with
statistical graphical methods
In our prospective identification
study, in-depth review of the
chronograph temporal patterns
proved a valuable component
of the expert review. Univariate
measures of temporal
association may over-simplify
or obscure the underlying
patterns in such rich, complex
and often long records [72]
Safety signal detection in
longitudinal observational data
should account for limitations
of the underlying data and take
measures to ensure appropriate
interpretation. In selecting the
data set for analysis, one should
account for both its size and
scope (which drugs and
diagnoses it captures) and for
the fact that effective review of
identified temporal associations
requires expert knowledge of
the underlying data, which is
particularly relevant for large
heterogeneous data sets
Our retrospective evaluation
against historical safety signals
for European centrally
authorised products showed
that none of them could be
detected in THIN with the
method we used, prior to the
initial signal at the EMA. In
many cases (to be further
specified once we have the
data), this was because of the
drug not being available on the
UK market at the time, or the
drug or medical event not being
reliably captured in primary
care
Future research should explore
the relative merits of
performing safety signal
detection in longitudinal
observational data for groups of
medicinal products and medical
events, instead of or in parallel
with that of individual products
and events
In our comparison to published
epidemiological studies, a
common discrepancy was that
they performed analysis for all
drugs in a class together and/or
for a number of related medical
events together, which
improves power. However, our
detailed review often found
substantial and important
differences among different
drugs in the same class or
among different medical events
in the same category.
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2.11 Signal Detection in Clinical Study Data
In the pre-approval phase of a drug, systematically col-
lected adverse event data from randomised clinical trials
are the principal data source and therefore the cornerstone
of safety analysis. Specifically, clinical trial data allow the
estimation of exposure, which is one of the limitations of
spontaneous reporting datasets [7]. In addition, randomi-
sation itself is a powerful feature of randomised controlled
trials that addresses the issue of confounding, which
otherwise complicates attempts to identify imbalances in
the incidence of adverse events between the treated and
untreated subjects in data from non-randomised sources.
Because of this, clinical trial data form a natural source for
signal detection, especially in the early phase of a drug’s
lifecycle.
Two different types of analyses performed in company
clinical trial databases are presented: in the first, the use of
extreme value modelling for the prediction of potential
drug toxicity was evaluated; in the second, different
approaches for dealing with multiplicity issues for adverse
event-based signal detection were compared.
It is often the case that potential drug toxicity is sug-
gested by the occurrence of extreme values of clinical
variables, rather than changes in the location of the dis-
tribution of these variables. For example, large values of
serum creatinine and blood urea nitrogen are used in the
diagnosis of acute renal failure, large values of the QT
interval are suggestive of cardiotoxicity and large values of
alanine aminotransferase suggest hepatotoxicity. Many
other examples of abnormally large (or small) values of
laboratory variables being indicative of safety issues can be
found in the Common Terminology Criteria guidelines,5
and, in general, any laboratory values that fall above the
upper limit of normal or beneath the lower limit of normal
may be indicative of a potential safety issue. Often,
extreme values are poorly predicted by an analysis that
focuses on the central features of the distribution. There-
fore, analyses of means or medians tend to be uninforma-
tive. Extreme value modelling might therefore provide a
novel approach to the prediction of drug toxicity early on
during drug development.
A retrospective analysis of phase II data using extreme
value modelling was conducted for ximelagatran [74], a
compound that was denied marketing approval in the USA
and was withdrawn from those markets in which it had
been approved because of concerns over potential liver
toxicity. The analysis showed that the phase II data were
predictive of the phase III results and, had the methods
been available at the time, such analyses would have
provided valuable information relating to the decision to
proceed with further development of the compound.
One important characteristic of signal detection in
clinical trials as well as in other databases is a focus on the
evaluation of a large number of endpoints. Analyses of
adverse event data typically generates multiple risk mea-
surement estimates associated with events across several
body systems. Selection of outcomes for further evaluation
by conventional hypothesis testing of between-group dif-
ferences for each endpoint can be problematic. Ignoring the
fact that the data determine the hypotheses that are tested,
by using a process that involves a large number of com-
parisons across multiple analysis time points multiplicity
becomes an issue. Acknowledging P-values as a useful
flagging device, ICH E9 recommends statistical adjust-
ments for multiplicity when applying hypothesis tests to a
large number of safety variables in clinical trial data.
However, probably owing to the concern of missing true
safety signals (i.e. false-negative signals), multiplicity
adjustment has also been described as counterproductive
and again probably because of these and similar reserva-
tions, adjustments are often avoided, despite the fact that
ignoring multiplicity may easily result in an excessive rate
of false-positive signals. The EudraVigilance Expert
Working Group notes that thresholds commonly used to
detect signals in spontaneous data are a trade-off between
two conflicting goals: ‘‘either generating too many false
positive signals if the threshold is too low or missing true
signals if this threshold is too high’’. Given this trade-off, it
is important to identify and calibrate methods to strike a
reasonable balance between these two parameters.
The objective of this study [75] was to investigate dif-
ferent approaches to address multiplicity for the use of
signal detection methods to select ADR candidates in
clinical trial data. The aim was to identify the best per-
forming method that maximises the proportion of correct
signals (i.e. the positive predictive value) as compared with
the CDS as the gold standard. In addition, the use of dif-
ferent MedDRA levels for signal detection reflects the
importance of considering the MedDRA hierarchy for
signal generation (see above, ‘Timeliness of Quantitative
Signal Detection using MedDRA Terms and Groupings’).
In addition to basing the analyses on the PT as the smallest
unit of analysis, the use of available company-specific
grouping of PTs developed specifically for the purpose of
labelling so-called medical labelling groupings was
evaluated.
As expected, the ability for ADR detection was highly
influenced by ADR frequency. In general, all model types
that took multiplicity into consideration proved appropriate
for the detection of signals. The Bayesian hierarchical
model that can make use of the hierarchy, thereby bor-
rowing strength, performed best among the quantitative
5 Common Terminology Criteria for Adverse Events, US National
Cancer Institute (http://ctep.cancer.gov/).
484 A. F. Z. Wisniewski et al.
signal detection methods, especially with regard to time to
signal. In our analysis, the use of medical labelling
groupings did slightly improve the performance of quan-
titative signal detection algorithms.
In summary, taking multiplicity into consideration
resulted in lower rates of false-positive signals. The hier-
archical Bayes and double-FDR, which also account for the
hierarchical structure of the underlying medical terminol-
ogy dictionary, demonstrated the best performance in the
investigated setting. Considering the good positive pre-
dictive value while providing similar sensitivity, these
methods can provide an alternative to the often-used
unadjusted analysis for identifying or flagging potential
imbalances between treatment arms and as such could be
used in the detection of ADR candidates. However,
selection of the most appropriate methods must consider
the size of the clinical trial database and computational
requirements.
3 Discussion
These recommendations are presented to highlight the
outcomes of the research conducted under the auspices of
IMI PROTECT Work Package 3 and in such a way that
pharmacovigilance professionals, particularly those with an
interest in research and methods development can readily
adopt appropriate potential improvements in their quanti-
tative signal detection practices. They should not be con-
sidered a comprehensive treatise on the subject of
quantitative signal detection but should be considered by
Recommendation Rationale
If prior knowledge suggests data
from a particular organ system
should be monitored, consider
extreme value modelling on
data arising from each trial for
the compound of interest. For
example, if preclinical data
suggested a potential liver
issue, prepare to model ALT; if
another compound in the class
showed kidney signals, prepare
to model creatinine
Extreme-value modelling has
been demonstrated, in various
examples, to provide useful
predictions of drug toxicities
from early-phase data. If it is
possible to pre-specify the
modelling and prediction
exercise, the results have
greater credibility than if they
are data driven, and resources
can be allocated up front to
ensure the work is done to
appropriate deadlines [74, 76]
Some analyses will be data
driven, suggested by observed
extremes in the data. These
could also be subjected to
extreme value modelling and
the statistical evidence thus
acquired interpreted in context
Not all potential safety issues are
known in advance, so some
analyses are necessarily data
driven. It is inappropriate to
consider such analysis
illegitimate or to yield
unreliable results provided they
are interpreted in context.
Statistical inference is only one
part of the larger process of
scientific inference [74]
Extreme value modelling can
commence as early as phase I;
however, in most cases, phase
II data need to be available for
reliable inferences to be made
Experience suggests that phase I
data may be sufficient for
extreme value modelling to
identify toxicity, but that
sometimes the sample sizes are
too small. Modelling and
prediction have the most value
to add when the volume of
available data is low, so such
exercises should be





or Safety Review Boards are
likely to benefit from extreme
value modelling of unblinded
data
When an IDMC exists, there are
sometimes reasons for
additional monitoring. It
follows that applying proven
methodology to emerging data
will provide the best chance of
identifying and characterising
the safety issue as soon as
possible [74]
When extreme value modelling
does not find evidence of a
safety signal in studies of short
duration, extrapolation beyond
observed durations of exposure
is discouraged
It is reasonable to expect that
some toxic effects of drugs will
not manifest themselves until
several weeks or months of
exposure have occurred. If
extreme values are not
observed at relevant doses in
short trials, proceed with
caution, acknowledging that
they could occur after longer
durations of exposure
Multiplicity adjustment provides
a useful tool to improve the
positive predictive value in
signal detection in clinical trial
data. The use of multiplicity
adjustment needs to be
evaluated against the size of the
available clinical trial database
The ability for ADR detection is
highly influenced by ADR
frequency in the source dataset.
Thus, database size and event
reporting frequency must be
taken into consideration when
the use of multiplicity
adjustments for ADR candidate
selection is considered [75]
The use of Bayesian Hierarchical
Models can improve the
efficiency of signal detection
through borrowing of strength
from other relevant events in
the clinical trial dataset. This





provided the best performance
with regard to positive
predictive value, specificity,
sensitivity and negative
predictive value, mainly owing
to their ability to ‘‘borrow
strength’’ across similar terms
[75]
The use of more specific
MedDRA groupings can
further improve signal
detection in clinical trial data
The use of narrow-term
groupings for analysis provided
slightly better results for signal
detection compared with the
analysis based on MedDRA
PTs alone [75]
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readers within the context of the entire body of signal
detection research and guidance documents that exist on
good signal detection practice [7, 77] outside of IMI
PROTECT. For example, PROTECT’s focus on quantita-
tive signal detection methods means that recommendations
relating to the relative merits of quantitative vs. qualitative
signal detection methods cannot be made and pharma-
covigilance organisations are likely to have to continue
with both approaches to maintain an optimal signal
detection capability. Although a broad cross-section of
databases [78] and data sources were employed in the work
package, the generalisability of recommendations to other
databases and data sources should be considered carefully
before implementing them, particularly in databases of
adverse event reports smaller than those used in this
project.
An important strength of PROTECT’s signal detection
research was the execution of standardised analysis pro-
tocols across multiple spontaneous reporting datasets [35,
45]. Several of these studies compared the databases of
pharmaceutical companies, national regulatory authorities,
and international organisations, such as the EMAgency and
the WHO.
PROTECT found no overall benefit in conducting signal
detection using MedDRA HLTs or SMQs compared with
using individual PTs [9]. Some relatively minor gain in
time to signalling was seen when closely related (in a
clinical sense) ADR terms were grouped together, an area
for potential future research. This is compatible with an
earlier study of the US FDA Adverse Event Reporting
System, which found that analysis at the level of HLTs or
SMQs decreased sensitivity but increased specificity. Its
reference dataset were drug-event combinations with some
degree of support in the literature that were not on the
original drug label, but it did not consider timeliness [8].
PROTECT showed that knowledge engineering techniques
can be used to derive novel groupings of adverse event
terms dynamically based on the relevant semantic dimen-
sions for a specific topic of interest, although no net
improvement in signal detection performance was seen in
these studies [16, 17]. It is interesting to speculate whether
it may be possible to go beyond this restricted example and
generate alternatives to the standard groupings available in
existing adverse event terminologies, such as MedDRA
HLTs or SMQs.
One of the tangible outcomes of PROTECT work
package 3 is the structured database of MedDRA coded
ADR information taken from section 4.8 of the SPC for all
products authorised in Europe through the centrally
authorised procedure [25]. This database is publically
available on the EMA website and is maintained. It reduces
the need for manual inspection of SPCs when the focus of
safety monitoring is detection of new risks. Its use has
already been tested and implemented into signal detection
processes at the EMA and the UMC.
In a broad study across spontaneous report databases,
PROTECT showed that the choice of signal detection
algorithm (e.g. threshold on the number of reports, the
threshold on the disproportionality statistic, and/or statis-
tical significance) was much more important than the
choice of disproportionality statistic itself [35]. Perfor-
mance of any single algorithm might be very different
between one spontaneous report database and another but
the relative performance of two algorithms was generally
similar across different databases. In a related study
across almost the same range of databases, the use of
stratification and subgroup analysis in disproportionality
analysis was explored [45]. An earlier study by Caster
et al. [37] showed that the use of subgroup analyses and
stratification both out-performed crude disproportionality
analysis although the relative contributions of each
approach were not determined. In the PROTECT study, it
was shown that subgroup analyses tended to be more
beneficial over stratified analyses across all datasets
studied. Subgroup analyses also provided clear benefits
over crude analyses in some datasets whereas stratified
analyses did not increase sensitivity or precision beyond
random variation. This unexpected finding that has not
been reported elsewhere has important implications
because a number of organisations routinely use stratifi-
cation in their analyses, but very few routinely employ
subgrouping. Other previous studies [36, 38] have
observed modest improvements for stratified analyses
consistent with the results from the stratified analyses in
the PROTECT study and therefore these findings from the
other studies may also be artefacts from the stratification
process rather than a true effect.
PROTECT explored the impact of masking on statistical
signal detection in spontaneous report databases [49, 50].
Under the conditions of the study, it was rare for masking
to affect whether a drug-event pair was considered to be
disproportionally reported or not; however, the drug-event
pairs that were affected in this way primarily involved
rarely reported ADRs. Furthermore, the study only con-
sidered removal of single masking drugs from the calcu-
lation and in some cases, multiple masking drugs may be
present [51].
For the detection of adverse DDIs, PROTECT showed
that statistical interaction measures with additive baseline
models outperform those with multiplicative baseline
models [55], typically available in standard statistical
software. This finding was true for both established and
emerging DDIs. Notably, for emerging adverse DDIs, the
statistical interaction measures with multiplicative baseline
models that might be the easiest to implement performed
worse than would expected by chance.
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Many organisations rely on rule-based methods for the
detection of duplicate individual case safety reports; how-
ever, PROTECT showed that probabilistic record matching
performed better than rule-based screening [57] and should
be considered as a viable alternative. Specifically, proba-
bilistic record matching demonstrated a high predictive
value above that of rule-based screening, and is expected to
improve efficiency and accuracy of duplicate management.
This has important resource and quality implications for
organisations where large volumes of case reports are
exchanged on a routine basis.
A comparison between estimates of association from
formal epidemiological studies and proportional reporting
ratios in spontaneous reporting data for a set of known
ADRs found a correlation, at a point in time before the
ADR was first publicly recognised [59]. This study sug-
gests that it may be possible to use the proportional
reporting ratio at the early phase of the analysis of a new
safety signal as an indicator of the likely strength of the
association, should the signal be confirmed. Acknowledged
limitations exist in the current evidence base for this
association and have been discussed in an earlier publica-
tion [60].
At present, signal detection is predominantly based on
spontaneous reports, but the use of longitudinal electronic
health data in pharmacovigilance is an area of active
research. Most studies to date have focussed on the sta-
tistical evaluation of well-established ADRs [79, 80] but
not sought to define processes for effective identification of
emerging safety signals in longitudinal health data. Simi-
larly, comparisons between individual case reports and
longitudinal health data for signal detection have focussed
on established and not emerging ADRs. Broad studies such
as those performed by observational medical outcomes
partnership and EU-ADR have explored the merits of dif-
ferent epidemiological designs when applied automatically
across broad ranges of drugs and outcomes [80–83] but
such studies have been primarily retrospective in nature,
and there is also a lack of studies to determine the relative
merits of exploratory screening vs. customised confirma-
tory analyses of longitudinal health data. Some research
has proposed signalling showing outputs requiring high-
lighting in both spontaneous reports and observational data
[84] but without attempting to assess the relative value of
the two data sources.
PROTECT performed research on statistical signal
detection in the THIN database of longitudinal electronic
health records from general practices in the UK. A process
for structured clinical and epidemiological assessment of
temporally associated prescriptions and events in electronic
health records was developed and evaluated. It showed that
important potential safety signals can be identified in these
data, whereas clinical and epidemiological review of
highlighted statistical associations is crucial to attain an
acceptable false-positive rate [72]. Conversely, a retro-
spective evaluation did not detect any of about 500 his-
torical safety signals in THIN, prior to the initial signal at
the EMA. In many cases, this was because of the drug not
being reliably captured in primary care data, and on a few
occasions to the drugs not having yet been marketed in the
UK. In contrast, some of the ADRs could be detected in
VigiBase, even when the analysis was restricted to spon-
taneous reports from the UK. This shows that compre-
hensive surveillance for early safety signals requires broad
population coverage as well as effective ascertainment of a
wide spectrum of newly marketed drugs and adverse
events. Concurrent research has found that even networks
of longitudinal observational databases can be under-
powered for rare adverse reactions, whereas common
adverse reactions should be possible to detect for com-
monly used drugs [85]. There is an increasing number of
observational databases available throughout the world for
potential pharmacoepidemiology and signal detection work
with each having widely varying characteristics, data
structure and data quality concerns. It would be necessary
to repeat the PROTECT analyses in these databases to
determine to what extent these findings are generalisable.
Before approval of a drug, information on adverse
events from clinical trials constitutes the primary basis for
safety analysis and signal detection. PROTECT explored
two statistical approaches to enhancing signal detection in
clinical trials. One study explored the utility of extreme
value modelling in early clinical studies as the basis for
predicting drug toxicity in the subsequent phases of clinical
development and evaluation [74]. A retrospective analysis
showed that extreme value analysis of phase II data would
have highlighted the risk for liver toxicity for a compound
eventually withdrawn from the market on account of this
risk. A second study evaluating different approaches to
adjust for multiplicity found that Bayesian Hierarchical
Models can improve signal detection performance through
borrowing strength from related adverse events in the
clinical trial dataset [75].
4 Conclusions
Over a period of 5 years, IMI PROTECT has addressed
key research questions relevant to the science of safety
signal detection. The resultant recommendations point to
pragmatic steps that those working in the pharmacovigi-
lance community can take to improve signal detection
practices, whether in a national or international agency or a
pharmaceutical company setting. PROTECT has also
pointed to areas of potentially fruitful future research and
some areas where further effort is likely to yield less.
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